~~<i id='2E34300DBE'><strike id='2E34300DBE'><tt id='2E34300DBE'><pre id='2E34300DBE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：focus 2025-10-01 22:17:11 - browse：49615

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Biogen walks away from Aduhelm, years after polarizing approval

leisure time

Wikipedia

leisure time

entertainment

hotspot

entertainment

ThisimagefromtheKansasDepartmentofRevenueshowsasampledriver'slicenseissuedbythestate'sDivisionofVehi

WSS

How generative AI ratchets up security threats for health systems

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

California man arrested in connection with serial murders of Mexican strip club workers

Trump seeks lengthy delay of classified docs trial, citing upcoming election

Merck, Johnson & Johnson CEOs will testify on high drug prices

focus

hotspot

leisure time

Sports medicine is finally prioritizing gender equality

Vertex non

23andMe had bad news about my health. I wish a person had delivered it

Medicare drug price negotiation legal challenge met with skepticism

Affirmative action in medical school literally saved lives

How corporate America is slashing DEI workers amid backlash to diversity programs

BioMarin wins approval for gene therapy to treat hemophilia A

The Affordable Care Act has saved billions in health care costs

Hepatitis C has a cure — but many Americans still lack access to it

Investment in vaccine development is lagging, report finds

Wikipedia

FTC sues over Novant Health acquisition of two N.C. hospitals

Neutralizing antibodies against HIV shows promise in children

Humana’s losses in Medicare Advantage tank its stock

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Health Care Service Corp to buy Cigna Medicare Advantage plans

Bernie Sanders is gearing up to subpoena pharma CEOs

leisure time

entertainment

hotspot

entertainment